← Back to patent-cliff list
BLU-924
Tier C — Watch / tradeBLU-924
Blueprint Medicines Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KRAS
Indications (approved)：Non-small cell lung cancer, Colorectal cancer, Solid tumour, 胰腺导管癌
Regional status
US
Phase II
2026-06-04
EU
Phase II
2026-06-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of BLU-924?
Approved indications include: Non-small cell lung cancer, Colorectal cancer, Solid tumour, 胰腺导管癌.
When does the BLU-924 patent expire?
No public expiry year is available for BLU-924 yet; this page updates once verified.
How do I get a quote for BLU-924 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29